Physician profile
Daniel M Luong
NPI 1811420508
$3,134.37
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $343 · 2021: $1,041 · 2022: $817 · 2023: $912 · 2024: $21.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $728.69 | 2020-2023 | Ozempic, Rybelsus |
| Amgen INC. | $579.19 | 2020-2024 | Otezla, Repatha, Prolia |
| Gilead Sciences, INC. | $561.50 | 2020-2023 | |
| Lilly USA, LLC | $189.99 | 2020-2023 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $122.79 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.52 | 2021-2023 | Jardiance |
| Antares Pharma, INC. | $117.14 | 2023 | Xyosted, Tlando, Nocdurna |
| Almatica Pharma LLC | $90.37 | 2023 | Loreev Xr |
| Glaxosmithkline, LLC. | $70.79 | 2020-2023 | Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $64.08 | 2021-2022 | |
| Dynavax Technologies Corporation | $60.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.74 | 2022-2023 | Gardasil 9, Vaxneuvance |
| Mylan Specialty L.P. | $35.18 | 2021 | |
| Ucb, INC. | $34.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.49 | 2023 | Spravato |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $31.56 | 2021-2023 | Talicia |
| Bayer Healthcare Pharmaceuticals INC. | $26.11 | 2023 | |
| Ironwood Pharmaceuticals, INC | $23.57 | 2021 | |
| Eisai INC. | $22.18 | 2022 | |
| Cequr Corporation | $21.20 | 2022 | |
| Abbvie INC. | $20.44 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.38 | 2022 | |
| Pfizer INC. | $19.79 | 2023 | |
| Viiv Healthcare Company | $19.20 | 2020 | |
| Depuy Synthes Sales INC. | $19.16 | 2023 | Orthovisc |
| Oyster Point Pharma, INC. | $18.67 | 2023 | Tyrvaya |
| Insulet Corporation | $16.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Luong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.